Bellicum Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Bellicum Pharmaceuticals's estimated annual revenue is currently $1.1M per year.
- Bellicum Pharmaceuticals received $Undisclosed in venture funding in April 2018.
- Bellicum Pharmaceuticals's estimated revenue per employee is $41,481
- Bellicum Pharmaceuticals's total funding is $289.6M.
Employee Data
- Bellicum Pharmaceuticals has 27 Employees.
- Bellicum Pharmaceuticals grew their employee count by -37% last year.
Bellicum Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$289.6M
Total Funding
27
Number of Employees
$1.1M
Revenue (est)
-37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Bellicum Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Technical Operations & Quality | Reveal Email/Phone |
2 | President & CEO | Reveal Email/Phone |
3 | Director - Clinical Supply Chain | Reveal Email/Phone |
4 | Clinical Document Control Specialist II/Clinical Reasearch Associate | Reveal Email/Phone |
5 | Senior Research Associate | Reveal Email/Phone |
6 | Clinical Document Control Associate | Reveal Email/Phone |
7 | Office Manager | Reveal Email/Phone |
8 | IT Support Specialist II | Reveal Email/Phone |
9 | Chief Development Officer (CDO) | Reveal Email/Phone |
10 | Sr. Process Development Associate | Reveal Email/Phone |
Bellicum Pharmaceuticals News
Bellicum Pharmaceuticals; Cells Medica; Elli Lilly and Company; Gilead Sciences; Juno Therapeutics; Novartis; Oxford Biomedica; Pfizer; Precision Bioscience...
Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies...
Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies...
Bellicum Pharmaceuticals (NASDAQ:BLCM) is offering to sell shares of its Series 1 preferred stock and warrants to purchase common shares in ...
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.4M | 27 | 0% | N/A |
#2 | $2.7M | 27 | N/A | N/A |
#3 | $2.7M | 27 | N/A | N/A |
#4 | $2.7M | 27 | N/A | N/A |
#5 | $35M | 27 | 8% | N/A |
Bellicum Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-10-28 | $4.5M | A | Article | |
| 2010-12-22 | $3.0M | Undisclosed | Article | |
| 2012-03-09 | $20.0M | B | AVG Ventures LP, Remeditex Ventures | Article |
| 2014-01-08 | $34.4M | B | AVG Ventures | Article |
| 2014-08-28 | $55.0M | C | Multiple | Article |
| 2017-03-31 | $69.0M | Undisclosed | Citigroup | Article |
| 2018-04-18 | $Undisclosed | Undisclosed | Citigroup | Article |